Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru

BMC Public Health

Table 6 Cost-effectiveness of PCVs (per LY gained) in increasing order of LYs

	LYs	Cost^a	Difference vs no vaccine			Incremental differences vs PCV-7 scenario
	LYs	Cost^a	LYs	Cost^a	ICER	LYs	Cost^a	ICER
No vaccine	12,988,553	23,570,416	-	-	-	-	-	-
PCV-7	12,992,507	45,641,050	3,954	22,070,634	5,582	-	-	-
PHiD-CV	12,993,206	43,544,180	4,653	19,973,764	4,293	699	−2,096,870	−3,000
PCV-13	12,993,226	46,952,004	4,673	23,381,588	5,004	20	3,407,824	170,391

^aCosts in 2009 US$ (discounted data).
ICER, incremental cost-effectiveness ratio; LY, life year; PCV, pneumococcal conjugate vaccine; PCV-7, 7-valent pneumococcal conjugate vaccine; PCV-13, 13-valent pneumococcal conjugate vaccine; PHiD-CV, 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine.

ISSN: 1471-2458